Background Aim of this prospective study was to predict response to neoadjuvant therapy in
breast cancer patients using an in vitro breast cancer spheroid model. Methods Three …

This retrospective study examined magnetic resonance imaging (MRI)–derived tumor
sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the …

Background Mammographic density (MD) is a risk factor for breast cancer (BC)
development, and recurrence. However, its predictive value has been less studied. Herein …

Background Generalizable population-based studies are unable to account for individual
tumor heterogeneity that contributes to variability in a patient's response to physician-chosen …

A single tumor marker is not enough to predict the breast pathologic complete response
(bpCR) after neoadjuvant chemotherapy (NAC) in breast cancer patients. We aimed to …

Purpose Pathological complete response (pCR) is the goal of neoadjuvant chemotherapy
(NAC) for the HER2-positive and triple-negative subtypes of breast cancer and is related to …

Background: Neoadjuvant chemotherapy (NACT) is the standard of care for the treatment of
locally advanced or non-metastatic breast cancer, which may increase the chances of breast …

Purpose The aim of this study was to combine clinical pathologic variables that are
associated with pathologic completer response (pCR) and relapse-free survival (RFS) after …

Background: Given the low chance of response to neoadjuvant chemotherapy (NACT) in
luminal breast cancer (LBC), the identification of predictive factors of pathological complete …

Background The pathological complete response of neoadjuvant chemotherapy for breast
cancer correlates with the prognosis for survival. Tumors may have different prognoses …